CU23470A1 - Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c - Google Patents

Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c

Info

Publication number
CU23470A1
CU23470A1 CU20040174A CU20040174A CU23470A1 CU 23470 A1 CU23470 A1 CU 23470A1 CU 20040174 A CU20040174 A CU 20040174A CU 20040174 A CU20040174 A CU 20040174A CU 23470 A1 CU23470 A1 CU 23470A1
Authority
CU
Cuba
Prior art keywords
hepatitis
virus
pharmaceutical compositions
compositions against
recombinant living
Prior art date
Application number
CU20040174A
Other languages
English (en)
Inventor
Lasa Alexis Musacchio
Ponce De Leon Liz Alvarez-Lajonchere
Rivero Nelson Acosta
Carrera Santiago Duenas
Aizpurua Ivis Guerra
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040174A priority Critical patent/CU23470A1/es
Priority to ARP050103317A priority patent/AR050451A1/es
Priority to MYPI20053696A priority patent/MY170516A/en
Priority to MX2007001749A priority patent/MX2007001749A/es
Priority to CNA2005800342987A priority patent/CN101035560A/zh
Priority to PCT/CU2005/000004 priority patent/WO2006015557A1/es
Priority to AU2005270612A priority patent/AU2005270612A1/en
Priority to CA002575293A priority patent/CA2575293A1/en
Priority to RU2007108290/13A priority patent/RU2353651C2/ru
Priority to KR1020077003636A priority patent/KR20070040814A/ko
Priority to JP2007525153A priority patent/JP2008508890A/ja
Priority to BRPI0514274-1A priority patent/BRPI0514274A/pt
Priority to EP05773842A priority patent/EP1787656A1/en
Priority to ZA200701079A priority patent/ZA200701079B/en
Publication of CU23470A1 publication Critical patent/CU23470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus de viruela aviar recombinantes para combinaciones proteicas basadas en antígenos del virus de la hepatitis C y su uso en composiciones farmacéuticas capaces de inducir una respuesta inmune celular contra el virus de la hepatitis C, despué de la administración de un número reducido de dosis. las composiciones farmacéuticas de esta invención son útiles para la prevención y tratamiento de infecciones asociadas con el virus de la hepatitis C en mamíferos.
CU20040174A 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c CU23470A1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU20040174A CU23470A1 (es) 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
ARP050103317A AR050451A1 (es) 2004-08-11 2005-08-09 Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c
MYPI20053696A MY170516A (en) 2004-08-11 2005-08-09 Recombinant live vectors and their use in pharmaceuticals compositions against hepatitis c virus
MX2007001749A MX2007001749A (es) 2004-08-11 2005-08-10 Vectores vivos recombinantes del virus de la viruela aviar y su uso en composiciones farmaceuticas contra el virus de la hepatitis c.
CNA2005800342987A CN101035560A (zh) 2004-08-11 2005-08-10 重组活禽痘病毒载体及其在抗丙型肝炎病毒的药物组合物中的应用
PCT/CU2005/000004 WO2006015557A1 (es) 2004-08-11 2005-08-10 Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de l a hepatitis c
AU2005270612A AU2005270612A1 (en) 2004-08-11 2005-08-10 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis C virus
CA002575293A CA2575293A1 (en) 2004-08-11 2005-08-10 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus
RU2007108290/13A RU2353651C2 (ru) 2004-08-11 2005-08-10 Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с
KR1020077003636A KR20070040814A (ko) 2004-08-11 2005-08-10 재조합 생 계두 바이러스 벡터 및 간염 ｃ 바이러스에 대한약학적 조성물로서의 이들의 용도
JP2007525153A JP2008508890A (ja) 2004-08-11 2005-08-10 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用
BRPI0514274-1A BRPI0514274A (pt) 2004-08-11 2005-08-10 vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc
EP05773842A EP1787656A1 (en) 2004-08-11 2005-08-10 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus
ZA200701079A ZA200701079B (en) 2004-08-11 2007-02-06 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis C virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040174A CU23470A1 (es) 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
CU23470A1 true CU23470A1 (es) 2009-12-17

Family

ID=40262893

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040174A CU23470A1 (es) 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c

Country Status (14)

Country Link
EP (1) EP1787656A1 (es)
JP (1) JP2008508890A (es)
KR (1) KR20070040814A (es)
CN (1) CN101035560A (es)
AR (1) AR050451A1 (es)
AU (1) AU2005270612A1 (es)
BR (1) BRPI0514274A (es)
CA (1) CA2575293A1 (es)
CU (1) CU23470A1 (es)
MX (1) MX2007001749A (es)
MY (1) MY170516A (es)
RU (1) RU2353651C2 (es)
WO (1) WO2006015557A1 (es)
ZA (1) ZA200701079B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
CU22642A1 (es) 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral

Also Published As

Publication number Publication date
ZA200701079B (en) 2008-07-30
AU2005270612A1 (en) 2006-02-16
AR050451A1 (es) 2006-10-25
RU2353651C2 (ru) 2009-04-27
CN101035560A (zh) 2007-09-12
MY170516A (en) 2019-08-08
RU2007108290A (ru) 2008-09-20
CA2575293A1 (en) 2006-02-16
EP1787656A1 (en) 2007-05-23
WO2006015557A1 (es) 2006-02-16
BRPI0514274A (pt) 2008-06-10
MX2007001749A (es) 2007-04-20
JP2008508890A (ja) 2008-03-27
KR20070040814A (ko) 2007-04-17

Similar Documents

Publication Publication Date Title
MX2009009226A (es) Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
EA200602137A1 (ru) Гидрогелевые препараты интерферона
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
UY28080A1 (es) Isómeros posicionales del ifn peg alfa 2a
ATE461710T1 (de) Nipah-virus-impfstoffe
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
AR101814A1 (es) Partícula de tipo virus flavivirus
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
DOP2024000172A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CL2024002624A1 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2026002249A2 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus
EP3741845A4 (en) RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION WITH IT
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
MX2022013195A (es) Uso de proteina surfactante d para tratar infecciones virales.
MX2019013874A (es) Peptidos y sus usos como agentes antivirales.
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
AR050451A1 (es) Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de la hepatitis c
ATE335507T1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
WO2020255009A3 (en) Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
CY1107371T1 (el) Αυξηση της θυμοσινης στην γενετικη ανοσοποιηση